FDA approves Abbott TriClip TEER system
Abbott (NYSE: ABT) announced that the FDA granted approval for its first-of-ts-kind TriClip transcatheter edge-to-edge repair (TEER) system.
Stay updated with breaking news from Edwards Evoque. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Abbott (NYSE: ABT) announced that the FDA granted approval for its first-of-ts-kind TriClip transcatheter edge-to-edge repair (TEER) system.
Abbott (NYSE: ABT) announced today that an FDA advisory committee ruled that the benefits of its TriClip outweigh the risks.
Edwards Lifesciences (NYSE:EW) announced today that the FDA granted approval for its Evoque tricuspid valve replacement system.
Edwards Lifesciences (NYSE:EW) announced that one-year results from the TRISCEND study demonstrated favorable outcomes.
Three-fourths of patients had at least a two-grade reduction in tricuspid regurgitation, and 88% were alive 1 year after treatment with the experimental device.